Rockefeller Capital Management
SRPT icon

Rockefeller Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Rockefeller Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$93.3K Buy
5,191
+65
+1% +$1.23K ﹤0.01% 3023
2026
Q1 		$112K Buy
5,126
+1,022
+25% +$19.8K ﹤0.01% 2814
2025
Q4 		$88.3K Buy
4,104
+2,034
+98% +$42.9K ﹤0.01% 2776
2025
Q3 		$39.9K Buy
+2,070
New +$36.9K ﹤0.01% 3022
2023
Q3 		– Sell
-8,120
Closed -$850K – 1795
2023
Q2 		$850K Buy
8,120
+3,978
+96% +$513K ﹤0.01% 1153
2023
Q1 		$570K Buy
4,142
+2,142
+107% +$278K ﹤0.01% 1300
2022
Q4 		$259K Sell
2,000
-5,545
-73% -$643K ﹤0.01% 1547
2022
Q3 		$834K Sell
7,545
-6,910
-48% -$696K ﹤0.01% 1078
2022
Q2 		$1.08M Sell
14,455
-974
-6% -$71.7K 0.01% 966
2022
Q1 		$1.21M Buy
15,429
+2,062
+15% +$158K 0.01% 994
2021
Q4 		$1.2M Buy
13,367
+4,926
+58% +$421K 0.01% 987
2021
Q3 		$780K Buy
8,441
+6,721
+391% +$518K ﹤0.01% 1093
2021
Q2 		$133K Sell
1,720
-81
-4% -$6.14K ﹤0.01% 1673
2021
Q1 		$134K Buy
1,801
+166
+10% +$15.3K ﹤0.01% 1484
2020
Q4 		$278K Sell
1,635
-8,036
-83% -$1.19M ﹤0.01% 1087
2020
Q3 		$1.36M Sell
9,671
-678
-7% -$103K 0.01% 524
2020
Q2 		$1.66M Buy
10,349
+141
+1% +$19.2K 0.02% 441
2020
Q1 		$998K Buy
10,208
+8,385
+460% +$958K 0.01% 483
2019
Q4 		$235K Buy
1,823
+47
+3% +$4.74K ﹤0.01% 733
2019
Q3 		$134K Sell
1,776
-81
-4% -$9.57K ﹤0.01% 709
2019
Q2 		$282K Sell
1,857
-11
-0.6% -$1.34K ﹤0.01% 525
2019
Q1 		$222K Buy
1,868
+11
+0.6% +$1.41K ﹤0.01% 582
2018
Q4 		$203K Hold
1,857
– – ﹤0.01% 403
2018
Q3 		$300K Buy
1,857
+632
+52% +$86.4K ﹤0.01% 313
2018
Q2 		$162K Buy
+1,225
New +$116K ﹤0.01% 346

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Rockefeller Capital Management's SRPT Position: Q2 2026 in Review

Rockefeller Capital Management increased its Sarepta Therapeutics (SRPT) stake by 1.3% in Q2 2026, buying an estimated $1.23K and bringing the position to 5,191 shares worth $93.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3023.

Rockefeller Capital Management first reported a position in SRPT in Q2 2018 and has held it in 25 quarters since. The position peaked at $1.66M in Q2 2020. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Rockefeller Capital Management held 5,191 shares of Sarepta Therapeutics worth $93.3K as of Q2 2026.
  • Rockefeller Capital Management bought 65 Sarepta Therapeutics shares in Q2 2026, an estimated $1.23K.
  • Sarepta Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3023 holding.
  • Rockefeller Capital Management first reported a position in Sarepta Therapeutics in Q2 2018 and has held it in 25 quarters since.
  • Rockefeller Capital Management's Sarepta Therapeutics position peaked at $1.66M in Q2 2020.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.